
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is a late-stage biopharmaceutical company with a strong pipeline of oral, small-molecule drug candidates focused on treating diabetes and other chronic diseases. The company's flagship candidate, cadisegliatin, has shown promising results in clinical trials as an adjunct therapy to insulin for people living with type 1 diabetes. With plans to initiate a Phase 2a Hybrid CATT1 trial before the end of 2026 and potential expansion into other indications, vTv's stock has a positive outlook with a price target of $42 and the potential for further upside. Key risks include safety concerns, lower than expected efficacy, competition, regulatory challenges, financing needs, and IP protection. However, with enthusiastic feedback from key opinion leaders and the potential for use in both adolescents and as a metabolic adjunct to emerging curative modalities, there is potential for vTv to reach new heights, with a revised price target of $57.
Bears say
vTv Therapeutics is facing numerous risks that could hinder the success of its clinical pipeline, including potential safety and efficacy issues in clinical trials, uncertainty of receiving marketing approval even with Special Assessment Protocol agreements, stiff competition in the T1D market, and potential delays in clinical trials due to reliance on third-party suppliers. Additionally, the company's financials and valuation may be negatively impacted by these risks, making it a risky investment. Therefore, as a financial analyst, a cautious approach is necessary when considering vTv Therapeutics's stock due to its inherent risks.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares